Aquinox Pharmaceuticals Announces Third Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Aquinox Pharmaceuticals Announces Third Quarter 2014 Financial Results

VANCOUVER, British Columbia, Nov. 4, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. ("Aquinox") (Nasdaq: AQXP ), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics for inflammatory disease and cancer, today provided a corporate update and reported financial results for the third quarter ending September 30, 2014.

"We continue to make steady progress in our ongoing Phase 2 clinical trials with AQX-1125. Both our FLAGSHIP trial, in patients with chronic obstructive pulmonary disease (COPD) exacerbations, and our LEADERSHIP trial, in patients with bladder pain syndrome/interstitial cystitis (BPS/IC), are advancing toward completion," said Mr. David Main, President and CEO of Aquinox. "Our efforts to open additional sites in the United States and work with existing sites for both trials have increased enrollment. I am also pleased to report that activities are well underway to initiate two new exploratory Phase 2 clinical trials investigating AQX-1125 in atopic dermatitis and chronic rhinosinusitis with nasal polyps."

Business Highlights

Enrollment of patients in FLAGSHIP, a Phase 2 trial of AQX-1125 in chronic obstructive pulmonary disease (COPD) exacerbations, is progressing towards completion. Enrollment is coming predominantly from northern hemisphere sites (United States and Northern/Central Europe) as winter is approaching and cold weather and upper respiratory tract infections are triggers for exacerbations. FLAGSHIP is designed to evaluate the safety and efficacy of AQX-1125 in approximately 350-400 unstable, moderate to severe COPD patients with a history of frequent exacerbations. Top line results are expected in the first half of 2015.

Enrollment of patients in LEADERSHIP, a Phase 2 trial of AQX-1125 in bladder pain syndrome/interstitial cystitis (BPS/IC), is progressing towards completion. The trial continues to enroll patients in clinical sites across Canada as well as 12 sites have been initiated across the United States. LEADERSHIP is designed to evaluate the safety and efficacy of AQX-1125 in approximately 70 female patients with BPS/IC. Top line results are expected in the first half of 2015.

Initiating trials in atopic dermatitis and chronic rhinosinusitis with nasal polyps. Aquinox is planning to initiate two additional exploratory Phase 2 trials with AQX-1125 in atopic dermatitis and chronic rhinosinusitis with nasal polyps. Aquinox expects to initiate at least one of these clinical trials before the end of 2014 with the second in the first half of 2015.

Summary of Financial Results

Cash Position. Cash, cash equivalents, short-term and long-term investments totaled $48.1 million as of September 30, 2014, compared to $13.8 million as of December 31, 2013. This increase was primarily driven by the proceeds from Aquinox's initial public offering, which was completed in March 2014. Aquinox expects its cash, cash equivalents, short-term and long-term investments to be sufficient to complete both ongoing Phase 2 trials and both planned exploratory Phase 2 trials.

R&D Expenses. Research and development expenses for the third quarter of 2014 increased to $5.3 million from $3.0 million in the third quarter of 2013. This increase was primarily due to the ongoing advancement of AQX-1125 through the FLAGSHIP and LEADERSHIP trials.

G&A Expenses. General and administrative expenses for the third quarter of 2014 increased to $1.0 million from $0.4 million in the third quarter 2013. This increase was primarily due to costs associated with operating as a public company.

Net Loss. Net loss for the third quarter of 2014 was $6.3 million compared to a net loss of $3.4 million for the third quarter of 2013. The increase in net loss was primarily due to the ongoing advancement of AQX-1125 through the FLAGSHIP and LEADERSHIP trials, and costs associated with operating as a public company.

About Aquinox Pharmaceuticals, Inc.

Aquinox is a clinical stage pharmaceutical company discovering and developing novel, small molecule therapeutics targeting SH2-containing inositol-5'-phosphatase 1 ("SHIP1") for the treatment of inflammatory disease and cancer. For more information, please visit www.aqxpharma.com .

Cautionary Note on Forward-looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to data availability from ongoing clinical trials and initiation of future clinical trials. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; our expectations regarding the potential safety, efficacy or clinical utility of AQX-1125; and reasons outside of our control. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and uncertainties faced by Aquinox is contained in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 filed with the Securities and Exchange Commission. Aquinox disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Info:

Brendan Payne
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
ir@aqxpharma.com

Bianca Nery
Senior Account Executive
MacDougall Biomedical Communications
650.339.7533
aquinox@macbiocom.com

     
AQUINOX PHARMACEUTICALS, INC.
Condensed consolidated and combined balance sheets
(Unaudited) (Expressed in U.S. dollars)
     
  SEPTEMBER 30, DECEMBER 31,
  2014 2013
Assets    
Cash, short-term and long-term investments $48,143,827 $13,826,992
Other current assets 360,096 1,469,359
Other long-term assets 111,445 352,755
Total assets $48,615,368 $15,649,106
     
Liabilities    
Current liabilities $4,571,782 $2,620,105
Non-current liabilities 63,708 4,863,987
Total liabilities $4,635,490 $7,484,092
     
Redeemable convertible preferred stock -- 73,858,722
     
Stockholders' equity (deficit) 43,979,878 (65,693,708)
Total liabilities, redeemable convertible preferred stock, and stockholders' equity (deficit) $48,615,368 $15,649,106
     
         
AQUINOX PHARMACEUTICALS, INC.
Condensed consolidated and combined statements of operations and comprehensive loss
(Unaudited) (Expressed in U.S. dollars)
         
  THREE MONTHS ENDED NINE MONTHS ENDED
  SEPTEMBER 30, SEPTEMBER 30,
  2014 2013 2014 2013
Operating expenses        
Research and development $5,323,015 $3,027,206 $11,753,749 $4,847,276
General and administrative 986,870 389,862 2,802,867 1,085,586
Total operating expenses 6,309,885 3,417,068 14,556,616 5,932,862
Other income (expenses)        
Bank charges and financing costs (2,455) (1,643) (458,651) (5,246)
Change in fair value of derivative liabilities 29,388 24,871 957,818 972,757
Amortization and extinguishment of remaining discount on preferred shares upon conversion of preferred shares -- (120,762) (1,884,233) (265,650)
Other income (expenses) (1,350) 142,071 4,943 36,701
  25,583 44,537 (1,380,123) 738,562
Net loss before income taxes (6,284,302) (3,372,531) (15,936,739) (5,194,300)
Income tax recovery 222 5,044 222 5,044
Net loss  $ (6,284,080)  $ (3,367,487)  $ (15,936,517)  $ (5,189,256)
         
Other comprehensive income – unrealized gain on available for sale securities  6,421 -- 7,301 --
Comprehensive loss  $ (6,277,659)  $ (3,367,487)  $ (15,929,216)  $ (5,189,256)
         
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 144

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 151

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 0

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
CJ BIO Bets on Better Taste for Cleaner Food Labels

Updated Category News Views 55

A bland reduced-salt sauce can wreck months of product development in one spoonful. That unglamorous reality sits underneath CJ BIO's November 17-19 appearance at Fi Europe 2026 in Frankfurt, where the company is pitching food makers on a simple but stubborn proposition: healthier-looking labels cannot come at the expense of taste. Flavor Is Still the Gatekeeper CJ BIO is...

Continue Reading
Wallstreet Sand Hands Its Massive Permian Plant to Wilbanks

Updated Category News Views 41

A sand plant can brag about acreage and horsepower all day, but frac crews remember who kept material arriving when a completion schedule got ugly. That is the real backdrop to PI Holdings and Wallstreet Sand Co. naming Blaine Wilbanks president of both businesses on November 18, 2026. This is not a ceremonial chair swap. Wallstreet has built an enormous Permian sand...

Continue Reading
Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 117

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Vusion's 2030 Plan Puts Recurring Revenue First At Scale

Updated Category News Views 30

Shelf labels are not exactly romance, yet Vusion has turned them into a serious growth machine. The 2030 plan is not really about hanging more electronic displays in aisles; it is about making those displays, sensors and store connections produce software and service revenue for years. That is the part of this story worth watching. The Hardware Base Is Becoming the Hook...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 65

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Hisense Year-End Push Tests Its Connected-Home Pitch

Updated Category News Views 45

A 300-inch picture is one heck of a way to sell a refrigerator. Hisense is rolling out year-end offers across the Middle East and Africa that stitch together its premium displays, connected appliances and ConnectLife software under one big household-upgrade pitch. It is glossy stuff, sure, but there is a practical commercial question underneath all the sparkle: can the...

Continue Reading
ZAKSIMLAB Tests Kombucha and Salmon Snack Pairing in Cafes

Updated Category News Views 171

A fish-based chip beside a fizzy tea mix is an odd little commercial wager, and that is exactly why ZAKSIMLAB's latest move deserves a look. The Seoul food brand launched Salmon Crunch Protein Chips in September, then put the snack next to its powdered kombucha at the 2026 Cafe & Bakery Fair Season 2. This is not a grand earnings story; no sales, pricing, store-count, or...

Continue Reading

Top 5 Most Recently Viewed Articles

Unisys to Engage with Investors at Sidoti Conference Soon

Updated Category News Views 137

Unisys to Connect with Investors at Sidoti Conference Soon Unisys (NYSE: UIS), a leader in technology solutions, is preparing to participate in the upcoming Sidoti Small-Cap Conference. This virtual event allows investors to hear directly from the company's executives, offering valuable insights. Meet with Unisys Executives The conference provides a fantastic chance for...

Continue Reading
VedaBio Welcomes Randy Rasmussen to Board of Directors

Updated Category News Views 341

VedaBio, a key player in biotechnology, took a bold step back in 2024 by appointing Randy Rasmussen, Ph.D., to its Board of Directors. This wasn’t just a casual hire; it’s an infusion of over 30 years of expertise into their operation. With Dr. Rasmussen at the helm, the chatter on the trading floor picked up—everyone was eyeing how this could reshape VedaBio's...

Continue Reading
Acuity Brands Sets Date for Fiscal 2025 First-Quarter Release

Updated Category News Views 99

Acuity Brands to Release Fiscal 2025 First-Quarter Results Acuity Brands, Inc. (NYSE: AYI) has announced an important date for investors and stakeholders. The company will release its fiscal 2025 first-quarter results on a Thursday morning, signaling its ongoing commitment to transparency and communication with its shareholders. Details of the Upcoming Announcement The...

Continue Reading
NV5 Global Successfully Secures Approval for Merger Deal

Updated Category News Views 166

NV5 Global Secures Stockholder Approval for Merger with Acuren Recently, NV5 Global, Inc. (NASDAQ: NVEE), a prominent provider of technology-driven engineering, testing, inspection, and consulting services, announced a major milestone. A significant majority of its stockholders voted in favor of the merger with Acuren Corporation, showcasing strong support for this...

Continue Reading
Why MacBook Users Shouldn't Worry About EU's USB-C Directive

Updated Category News Views 395

Understanding the New EU USB-C Directive The recent implementation of the EU’s USB-C directive has stirred discussions among electronics users, particularly MacBook owners. Effective from 2025, this directive mandates that mobile devices, including smartphones and tablets, must incorporate a USB-C port for charging. The significance of this directive extends beyond just...

Continue Reading